Trial Condition(s):
BAY58-2667, iv dose titration over 6h infusion in patients
11615
Not Available
Not Available
Primary objective:
Part A: To investigate the hemodynamic and subjective effects on dyspnea as well as well-being of the subjects following 3 intravenous (IV) doses of BAY 58-2667 given over 2 h per dose step in a dose escalation manner.
Part B: To investigate the hemodynamic effects of BAY 58-2667 given IV over 6 h.
Secondary objectives:
Part A: To investigate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of the respective dose levels.
Part B: To investigate the safety, tolerability, PD, PK, and subjective effects on dyspnea of the respective dose levels of BAY 58-2667.
- Critically ill subjects - Male (older than 18 years ) and female (older than 55 years) - Admitted to hospital with decompensated chronic CHF and clinical indication for parenteral pharmacotherapy with invasive hemodynamic monitoring and a pulmonary capillary wedge pressure of ≥18 mmHg - Postmenopausal female subjects or women without child bearing potential based on surgical treatment like bilateral tubal ligation, bilateral ovariectomy, or hysterectomy
- Women with childbearing potential; - Heart failure NYHA Class I and II - Acute heart failure (blood pressure <100 mmHg systolic or <60 mmHg diastolic, need for acute cardiological intervention or surgery, cardiogenic shock, primary need for catecholamines, need for invasive mechanical ventilation) - Unstable subjects - Subjects with acute coronary syndrome; - Renal insufficiency with serum creatinine ≥2 mg/dL (177 µmol/L); - Participation in another clinical trial during the preceding 3 months; - Resting heart rate in the awake subject below 45 BPM or above 120 BPM; - Relevant pathological changes in the ECG such as a second or third-degree AV block - Medical disorders, condition or history that would impair the subject’s ability to participate or complete this study including the history of relevant diseases of vital organs, of the central nervous system; and febrile illness within 1 week before the start of the study - Subjects with a history of severe allergies, non-allergic drug reactions, or multiple drug allergies or with hypersensitivity to the investigational drug, the control agent and/ or to inactive constituents
Locations | |
---|---|
Locations HELIOS Klinikum Erfurt GmbH Erfurt, Germany, 99089 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations St.-Johannes-Hospital Dortmund Dortmund, Germany, 44137 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Evangelisches und Johanniter Klinikum Duisburg, Germany, 47137 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Heliols Klinikum Wuppertal Wuppertal, Germany, 42117 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Schüchtermann Klinik Herzzentrum Osnabrück/Bad Rothenfelde Bad Rothenfelde, Germany, 49214 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Kerckhoff-Klinik GmbH Bad Nauheim, Germany, 61231 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Med. Fakultät der Martin-Luther-Universität Halle-Wittenberg Halle, Germany, 06120 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Johannes-Gutenberg-Universität Mainz Mainz, Germany, 55131 | Contact Us: E-mail: [email protected] Phone: Not Available |
Proof of concept study to investigate the impact of BAY 58-2667 given intravenously in patients with acute decompensated chronic congestive heart failure
Trial Type:
Interventional
Intervention Type:
Drug
Trial Purpose:
Treatment
Allocation:
Non-randomized
Blinding:
Open Label
Assignment:
Parallel Assignment
Trial Arms:
3